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ABsTrACT 
Acute lung injury is a neutrophil-dominant, life-
threatening disease without effective therapies and 
better understanding of the pathophysiological 
mechanisms involved is an urgent need. Here we 
show that interleukin (IL)-22 is produced from innate 
lymphoid cells (ILC) and is responsible for suppression of 
experimental lung neutrophilic inflammation. Blocking 
prostaglandin E2 (PGE2) synthesis reduces lung ILCs 
and IL-22 production, resulting in exacerbation of lung 
neutrophilic inflammation. In contrast, activation of the 
PGE2 receptor EP4 prevents acute lung inflammation. 
We thus demonstrate a mechanism for production of 
innate IL-22 in the lung during acute injury, highlighting 
potential therapeutic strategies for control of lung 
neutrophilic inflammation by targeting the PGE2/ILC/
IL-22 axis.
InTroduCTIon
Acute lung injury (ALI)/acute respiratory distress 
syndrome (ARDS) is a life-threatening neutro-
phil-dominant disease with a significant morbidity 
and mortality for which effective therapies are 
currently lacking.1 Excessive pulmonary neutrophil 
recruitment mediates lung tissue damage, despite 
the beneficial role of neutrophils in promoting 
tissue repair.2 Therefore, there is a need for more 
effective medicinal agents for use in these severe 
and often lethal lung injury syndromes.1 
Interleukin (IL)-22 is an IL-10 family member 
cytokine that is produced by both adaptive and 
innate immune cells. Recently, type 3 innate 
lymphoid cells (ILC3s) have been identified as the 
main source of innate IL-22.3 IL-22 is expressed 
in healthy human lung tissue, and patients with 
sarcoidosis and ARDS have decreased IL-22 levels.3 
Innate IL-22 is protective against acute epithelial 
damage and inflammation in the lung as neutral-
isation of IL-22 exacerbates bacterial and viral 
infections and exogenous IL-22 attenuates bacterial 
pneumonias.4
Non-steroidal anti-inflammatory drugs (NSAID) 
inhibit cyclooxygenase activity and subsequent 
production of prostaglandins and are very widely 
used to manage many inflammatory conditions. 
Use of NSAIDs worsens lung bacterial infections 
and is a risk factor for severe sepsis.5 In contrast, 
prostaglandins including prostaglandin E2 (PGE2) 
are used for treating critical lung diseases with 
improved oxygenation and decreased pulmonary 
artery pressures.6 PGE2 exerts its biological actions 
through engagement of its four receptors, namely 
EP1–4. We have recently found that PGE2 promotes 
IL-22 production from both T cells and ILC3s.7 8 
In this study, we have investigated the hypothesis 
that PGE2 inhibits acute lung neutrophilic inflam-
mation through modulating lung ILC3 production 
of IL-22.
MeThods
Wild-type C57BL/6 mice were purchased from 
Harlan UK. Rag1-/- mice and mice with selec-
tive EP4 deficiency in T cells (LckCreEP4fl/fl mice 
by crossing LckCre mice to EP4-flox mice)9 were 
maintained under specific pathogen-free condi-
tions in accredited animal facilities. Mice were 
aged >7 weeks old at the beginning of use. All 
experiments were conducted in accordance with 
the UK Scientific Procedures Act of 1986 and had 
local institutional ethical approval. The ALI mouse 
model was induced by intratracheal injection of 
10 µg of lipopolysaccharide (LPS) in combination 
with recombinant IL-22, EP2 and/or EP4 agonists, 
or indomethacin when indicated. After 24 hours, 
bronchoalveolar lavage (BAL) fluid and lung 
tissues were collected. Immune cells and cytokine 
production were measured by flow cytometry or 
ELISA. All data were expressed as mean±SD. The 
Student’s t-test or Mann-Whitney U test was used 
for statistical analyses by Prism V.6 (GraphPad) and 
p<0.05 was considered statistically significant.
resulTs
To study the cellular sources of innate IL-22 in the 
lung, we administered a low dose (10 µg) of LPS 
to Rag1-/- mice, which have no adaptive T and B 
cells, and analysed IL-22 production from various 
lung immune cells 24 hours later using flow cytom-
etry. In naïve mice, very few (~0.1%) CD11b+CD-
11c+Ly-6G− mononuclear phagocytes (MNP) 
or CD11b+Ly-6G+ neutrophils produced IL-22, 
while ~0.4% CD11b−CD11c−Ly6G-CD90.2+ 
of ILCs expressed IL-22 (figure 1A,B and online 
supplementary figure). Intratracheal adminis-
tration of LPS to the lung strikingly increased 
IL-22 production from ILCs by 10-fold to ~4% 
(n=3, p=0.004), but not from MNPs or neutro-
phils (figure 1A,B and online supplementary 
figure). The mean fluorescence intensity of IL-22 
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was significantly enhanced by LPS from ILCs (p=0.00007), 
suggesting that IL-22 production was also increased at the single 
cell level (figure 1C). Consistently, in response to appropriate 
stimulus lung innate immune cells produced IL-22 (figure 1D). 
IL-22 has been demonstrated to protect against inflammation at 
mucosal sites including the lung.3 To test whether IL-22 protects 
against ALI, we administered recombinant IL-22 intratrache-
ally into mice immediately before LPS challenge. Exogenous 
IL-22 significantly suppressed LPS-induced acute lung neutro-
philic inflammation (p=0.006) but had little effect on BAL total 
protein levels (figure 1E, n=3–5).
We have previously shown that PGE2 promotes intestinal 
ILC3 activation and IL-22 production.7 To examine whether 
PGE2 similarly regulates lung ILC3s and whether this leads 
to suppression of acute lung inflammation, we treated naïve 
mice with indomethacin, a cyclooxygenase inhibitor that 
inhibits endogenous PGE2 synthesis. Administration of indo-
methacin significantly reduced IL-22-producing ILC3s in 
the lung (figure 2A, n=4, p=0.048). In agreement with an 
increase in IL-22-producing ILC3s (figure 1A–C), LPS also 
induced accumulation of lung RAR-related orphan receptor 
gamma T (RORγt)+ ILC3s (p=0.027) and elevated BAL IL-22 
levels (p=0.015, figure 2B,C). Coadministration of indometh-
acin decreased LPS-induced accumulation of RORγt+ ILC3s 
(p=0.019, n=4–8) and IL-22 production (p=0.023, n=3–9) 
in the lung (figure 2B,C). This reduction of ILC3s and IL-22 
was associated with augmented LPS-induced acute lung neutro-
philic inflammation (figure 2D, p=0.035, n=3–4). Inhibition of 
endogenous PGE2 downregulated genes responsible for IL-22 
signalling (eg, IL-22, IL-22Rα) and lung epithelial barrier func-
tion (eg, ZO-1, Occludin) but upregulated S100A8/S100A9, 
which mediate neutrophilic lung inflammation (figure 2E). We 
Figure 1 Production of IL-22 from ILCs in response to acute lung injury. (A) Representative flow cytometric dot plots for IL-22 expression in lung 
CD45+CD11b−CD11c−Ly-6G− ILCs, CD45+CD11b/CD11c+Ly-6G− MNPs and CD45+CD11b+Ly-6G+ Neu from Rag1-/- mice administered intratracheally 
with LPS for 24 hours (n=3 for each group). Lung cells were restimulated with IL-23 ex vivo for 4 hours before intracellular staining. (B, C) Percentages 
and MFI of IL-22+ cells. (D) Innate IL-22 production from lung immune cells isolated from naïve Rag1-/- mice and then cultured in vitro with indicated 
cytokines for 3 days (n=3). (E) Neutrophil numbers and total protein levels in BAL from mice administered intratracheally with PBS (n=3–4) or LPS in 
the absence (PBS, n=5) or presence of recombinant IL-22 (rIL-22, n=4). P values are calculated by Student’s t-tests. BAL, bronchoalveolar lavage; IL, 
interleukin; ILC, innate lymphoid cell; LPS, lipopolysaccharide; MFI, mean fluorescence intensity; MNP, mononuclear phagocyte; Neu, neutrophil; PBS, 
phosphate buffered saline. 
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then examined whether exogenous activation of PGE2 signalling 
prevented ALI using selective EP2 or EP4 agonists. The EP4, but 
not EP2, agonist markedly suppressed LPS-induced neutrophil 
accumulation (figure 2F, n=5–6, p=0.005), and coactivation of 
EP2 and EP4 receptors reduced total protein levels in the BAL 
(figure 2F, p=0.007), suggesting that PGE2-EP4 signalling limits 
neutrophilic lung inflammation. Because PGE2 also promotes 
adaptive IL-22 production from T cells,8 we examined whether 
T cells are involved in PGE2-modulated ALI using Lck
CreEP4fl/
fl mice. Deletion of EP4 in T cells did not affect LPS-induced 
neutrophil accumulation or total proteins in the BAL (figure 2G, 
n=5–7), further indicating that PGE2-EP4 signalling is impor-
tant via a mechanism that stimulates innate IL-22 production 
from lung ILC3s.
dIsCussIon
Numerous experimental and clinical observations have shown 
that IL-22 plays a critical role in the control of mucosal injury 
and inflammation including pneumonia and ALI.3 This study 
further demonstrates that lung ILC3s are the major contrib-
utors of innate IL-22, which displays protective actions 
against neutrophilic inflammation in the airway. IL-22 has 
been reported to either protect against or promote allergic 
lung inflammation in the absence or presence of IL-17, 
respectively, suggesting that IL-22 functions in the lung in 
context-dependent manners.10 To augment IL-22 production 
or signalling, several approaches could be used, for example, 
application of IL-22 in protease-resistant forms via oral or 
intrapulmonary delivery or application of small chemical 
molecules that promote IL-22 production.3 Our findings show 
that PGE2 and its analogues (eg, EP4 agonists) could be used 
to catalyse the ILC3-IL-22 cascade and to facilitate the control 
of acute lung inflammation (figure 2H). Many lung cell types 
(eg, macrophages, damaged epithelial cells and neutrophils) 
can produce PGE2, which is essential to maintain ILC3 home-
ostasis and activation.7 Our findings highlight potential thera-
peutic strategies for control of lung neutrophilic inflammation 
by targeting the PGE2/ILC3/IL-22 pathway. It is envisioned 
that targeting this pathway by pharmacological intervention 
could have potential for the development of novel strategies 
for the treatment of lung inflammation especially in diseases 
where the neutrophil plays a prominent role.
Figure 2 PGE2 promotes innate IL-22 production from lung ILC3s and inhibits acute lung injury. (A) IL-22-producing ILC3s in the lung from mice 
administered with vehicle or indomethacin for 5 days (n=4 for each group). Lung cells were restimulated with IL-23 ex vivo for 4 hours before staining. 
(B–E) Mice were administered with indomethacin (Indo) or vehicle control (Veh) via drinking water for 4 days and then challenged intratracheally 
with PBS or LPS. Lung tissue and BAL fluid were harvested at 24 hours after LPS or PBS challenge. Lung RORγt+ ILC3s (B, n=8, 8, 3), BAL IL-22 levels 
(C, n=8, 9, 3) and neutrophils (D, n=3, 4, 3) in the BAL were measured by flow cytometry. (E) Summarised gene expression in lung tissues determined 
by quantitative real-time PCR. Expression level for each gene in the vehicle group was set as 1 (n=4 for each group). (F) BAL neutrophil numbers and 
total protein levels in mice administered intratracheally with PBS or LPS plus an EP2 agonist (Butaprost), an EP4 agonist (L-902,688) or both (n=5–
6 mice per group). (G) BAL neutrophil numbers and total protein levels in EP4fl/flLckCre (n=7) or control EP4fl/fl (n=5) mice administered intratracheally 
with LPS. P values are calculated by Student’s t-tests or Mann-Whitney U tests. (H) Proposed mechanistic schematic diagram for PGE2 functions on 
restriction of acute lung neutrophilic inflammation through amplifying the ILC3/IL-22 pathway. BAL, bronchoalveolar lavage; IL, interleukin; ILC, innate 
lymphoid cell; LPS, lipopolysaccharide; PBS, phosphate buffered saline; PGE2, prostaglandin E2. 
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Despite these important novel findings, we acknowledge this 
report has several limitations. First, the numbers of animals 
used in experiments were limited, so further validation of the 
findings may be needed by increasing mice numbers. Second, 
therapeutic effects of PGE2 analogues and rIL-22 on established 
neutrophilic lung inflammation induced by LPS or by other 
stimuli were not examined. Third, we have shown that exog-
enous IL-22 prevented ALI and that blocking PGE2 signalling 
reduced numbers of IL-22+ ILC3s in the lung. However, given 
the multiple roles of IL-22 in lung homeostasis as well as injury/
inflammation, further studies to determine direct roles of endog-
enous IL-22 in ALI are warranted. Fourth, the protective actions 
of the PGE2/ILC3/IL-22 axis have not been examined in human 
patients with ALI/ARDS, although findings from our mouse 
studies could have important translational implications.
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